Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis?

Annals of the Rheumatic Diseases

Volumn 64, Issue 10, 2005, Pages 1443-1450

  Koivula, M K ^a   Aman S ^a   Karjalainen, A ^a   Hakala, M ^b   Risteli, J ^a,c  

^a UNIVERSITY OF OULU   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; AUTOANTIBODY; CITRULLINE; COLLAGEN ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 2; PEPTIDE; PEPTIDE ANTIBODY; TELOPEPTIDE; AUTOANTIGEN; COLLAGEN; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BINDING; RHEUMATOID ARTHRITIS; ADOLESCENT; ANTIBODY SPECIFICITY; BINDING COMPETITION; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; BINDING, COMPETITIVE; COLLAGEN; COLLAGEN TYPE I; COLLAGEN TYPE II; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC;

EID: 27744595134     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.031211     Document Type: Article

References (22)

1. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis, the antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.
2. Young B, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. BMJ 1979;ii:97-9.
3. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognised by rheumatoid arthritis specific autoantibodies. J Clin Invest 1998;101:273-81.
4. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis associated antifilaggrin autoantibodies are post-translationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162:585-94.
5. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria (or the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
6. van Boekel MA, Vossenaar ER, van den Hoogen F, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.
7. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
8. Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
9. Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
10. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
11. Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005;10:54-64.
12. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001;166:4177-84.
13. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-SA antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:R142-50.
14. Holmdahl R, Bockermann R, Bäcklund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice - a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-47.
15. 125-radioimmunoassay. Arthritis Rheum 1983;26:832-40.
16. Claque RB, Shaw MJ, Holt P. Incidence and correlation between serum IgG and IgM antibodies to native type II collagen in patients with chronic inflammatory arthritis. Ann Rheum Dis 1981;40:6-10.
17. Rowley M, Tait B, Mackay IR, Cunninghan T, Phillips B. Collagen antibodies in rheumatoid arthritis. Significance of antibodies to denatured collagen and their association with HLA-DR4. Arthritis Rheum 1986;29:174-84.
18. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chem Acta 2004;350:17-34.
19. Nomura K. Specificity and mode of action of the muscle-type protein-arginine deiminase. Arch Biochem Biophys 1992;293:362-9.
20. Orgel JP, Wess TJ, Miller A. The in situ conformation and axial location of the intermolecular cross-linked non-helical telopeptides of type I collagen. Structure Fold Des 2000;8:137-42.
21. van Venrooij WJ, Pruijn G. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000;2:249-51.
22. Visser H, Ie Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum, 2002;46:357-65.